Special Report: You Could Lose or Make a Fortune

Todd Campbell

Todd Campbell


Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent articles


Why Co-Diagnostics Skyrocketed 28.3% Today

The FDA has approved emergency use of its at-home COVID-19 test.


Why Alector Is Tumbling 28.7% Today

Investors appear nervous that COVID-19 precautions could create obstacles to trials evaluating its lead drug candidate.


Why Medpace Holdings Is Skyrocketing 13.5% Higher Today

The clinical trial company's second-quarter financial results were better than expected.


Jazz Pharmaceuticals Wins FDA Approval for Its New Narcolepsy Drug

Xywav has been shown to reduce both cataplexy and excessive daytime sleepiness in narcolepsy patients.


Why CytoSorbents Is Soaring 12% Today

The company has priced its recently announced stock offering.


Gilead Sciences Invests $300 Million in an Immuno-Oncology Startup

The biopharma giant is acquiring 49.9% of privately-held Tizona Therapeutics.


Here's Why OPKO Health's Stock Is Skyrocketing 23% Today

The company confirmed it will provide coronavirus testing for the National Football League.


Here's Why Tricida Is Tanking 38.5% Today

The FDA has noted deficiencies in the application for approval of its only drug in development.


Why Waters Stock Is Skyrocketing 12.9% Today

The healthcare company's second-quarter results appear better than expected.


Here's Why Dynavax Is Surging 6.1% Today

Enrollment has begun in an early stage coronavirus vaccine trial utilizing Dynavax's technology.


Blueprint Medicines Inks Deal With Roche Worth Up to $1.7 Billion

Roche is licensing commercial rights to Blueprint Medicines RET-inhibitor pralsetinib.


Why InMode Shares Are Soaring 13.7% Today

The medical device maker's boosting its second-quarter guidance.


Here's Why Retractable Technologies Is Skyrocketing 22% Today

The company's been awarded a multimillion-dollar government COVID-19 contract to expand production of needles and syringes.


GlaxoSmithKline Inks New COVID-19 Vaccine Research Pact

Medicago is using GlaxoSmithKline's vaccine adjuvant in its clinical-stage COVID-19 vaccine.


Turning Point Therapeutics Licenses Its Lung Cancer Drug in China

Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.


Why Bellus Health Stock Tanked 69.2% Today

The company's lead drug has failed a phase 2 trial.


Why MEI Pharma Is Tanking 15.3% Today

A trial evaluating its most advanced drug has been discontinued because of a lack of efficacy.


Why COVID-19 Vaccine Developer Dynavax Is Down 6.5% Today

Pfizer released intriguing data regarding its own COVID-19 vaccine.


Why Translate Bio Crashed 21% Today

The clinical-stage vaccine developer, which is working on a COVID-19 vaccine candidate, announced it's selling more shares to the public.


uniQure Inks $2 Billion Licensing Deal With CSL Behring

Agreement licenses the rights for a promising hemophilia B gene therapy.